CORE--OPTICS AND PHOTODYNAMIC THERAPY DOSIMETRY

核心--光学和光动力治疗剂量测定

• 批准号: 6102735
• 负责人: WILLIAM R POTTER
• 金额: $ 21.92万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-09 至 2000-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102735
• 关键词: biomedical facility; disease /disorder model; dosage; human subject; laboratory mouse; neoplasm /cancer pharmacology; neoplasm /cancer photoradiation therapy; nonvisual photosensitivity; optics; pharmacokinetics; photosensitizing agents; radiation dosage

The overall aim of Core B, the Optics and PDT Dosimetry Core, is to provide support for the light delivery for PDT both in the clinic and in the laboratory. This include the setup for the light delivery devices (lasers, fibers, beam splinters) for both clinical and laboratory photodynamic therapy. PDT in both the laboratory and clinic requires proper dosimetry. The Core provides equipment and personnel to support the research of the projects and works to maximize the yield of useful information. To perform this function it is necessity to understand the dosimetry of PDT. This leads an effort in modeling. The limited understanding of dosimetry as dependent on the light and a drug has been expanded through study of the QSAR data on the pyropheophorbide hexyl ether series to include a sensitive target for PDT. We intend to continue to study the dosimetry of PDT in an attempt to support and provide a testable model framework in which to understand the results of the other projects in the overall study of structure activity relationships. Core personnel will perform laser maintenance, calibration and dosimetric measurements required by the clinical and laboratory research activities of the projects. The specific aims of Core B are: i. Technical support for clinical and scientific lasers; ii. Measurement of photobleaching during therapy; iii. Measurement of the total attenuation of tumor and normal tissue in patients undergoing PDT for the treatment of skin tumors; iv. Study of the pharmacokinetics of pyropheophorbide hexyl ether and subsequent series and ALA; v. PS distributions in frozen sections of tumors and normal tissues; vi. Refining the analytic framework of PDT targeting and dosimetry.

核心 B（光学和 PDT 剂量测定核心）的总体目标是 为临床和临床中的 PDT 光传递提供支持 实验室。这包括光传输设备的设置 （激光、光纤、光束分裂）用于临床和实验室 光动力疗法。 实验室和诊所的 PDT 都需要适当的剂量测定。核心 提供设备和人员支持项目的研究 并致力于最大限度地提高有用信息的产量。要执行此操作 功能 有必要了解 PDT 的剂量测定。这导致 建模方面的努力。对剂量测定的有限理解取决于 通过对 QSAR 数据的研究，光和药物得到了扩展 焦脱镁叶绿酸己基醚系列包括敏感靶标 太平洋夏令时。我们打算继续研究 PDT 的剂量测定，试图 支持并提供可测试的模型框架来理解 结构活动总体研究中其他项目的结果 关系。核心人员进行激光器维护、校准 以及临床和实验室所需的剂量测量 项目的研究活动。 核心 B 的具体目标是： 我。临床和科学激光的技术支持； 二.治疗期间光漂白的测量； 三.肿瘤和正常组织总衰减的测量 接受 PDT 治疗皮肤肿瘤的患者； 四.焦脱镁叶绿酸己醚的药代动力学研究 后续系列和ALA； v. 肿瘤和正常组织冰冻切片中PS的分布； 六.完善 PDT 靶向和剂量测定的分析框架。